CXCL10 and neoplasm: For example, JAK/STAT inhibitors such as ruxolitinib and tofacitinib, currently approved for inflammatory and autoimmune diseases, are being investigated in cancer to suppress pathological immune activation and reduce chronic inflammation triggered by CXCL10, which could otherwise promote tumor growth and immune evasion.